Modeling Endpoints: How to Model Anti-Drug Antibody Data in Nonclinical Studies
Welcome to the site for the "Investigating Endpoint Modeling - How to Model Anti-Drug Antibody Data in Nonclinical Studies" project group.
This page describes high-level project management details on the group, including purpose, milestones, attendees, and so on. We are part of the FDA/PhUSE Computational Sciences Nonclinical Working Group. Learn more about the larger working group at Non-Clinical Road-map and Impacts on Implementation.
Working Group Overview
- Determine endpoints
- Call for Participants
- Maintain wiki (ongoing)
- Research CDISC ADA
Call for participation!
What is the commitment?
- Time (minimum of 1 hour every two weeks for team meetings, up to 3 hours / month)
- Expected to contribute, not just be a spectator
- Contribution of viewpoints and content
- Wiki - creating/reviewing page content
If you would like to participate, please contact the co-leads for this group: Mike Wasko (firstname.lastname@example.org) and Debra Oetzman (email@example.com)
Work Group Participants
- Mike Wasko, PDS
- Gretchen Dean, Pfizer
- Thomas Gade Bjerregaard
Conference Calls and Minutes
Last revision by Mwasko79, 2017-06-14